BackTable Urology

What does it take to save both life and function in a rapidly progressing infection? In this episode of BackTable Urology, Dr. Judith Hagedorn (University of Washington) joins Dr. George Koch (Ohio State University) to unpack the complexities of Fournier’s gangrene management.

---

SYNPOSIS

They discuss advances in surgical techniques like skin-sparing debridement and the value of high-volume centers for patient outcomes. They also explore the use of wound vacuums, the challenges related to testicular management, and the future of Fournier’s gangrene treatment, including early detection and better patient scoring systems.

---

TIMESTAMPS

0:00 - Introduction
3:04 - Evolution of Fournier’s Management
7:50 - Management at High-Volume vs. Community Centers
20:39 - Use of Wound Vacs
27:03 - Testicular Management
43:56 - Future Directions

As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for invasive cystoscopies? In part five of the 2025 BackTable NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam engages in an insightful discussion with Dr. Sarah Psutka from the University of Washington and Dr. Katie Murray from NYU about the complexities and potential benefits of using biomarkers in non-muscle invasive bladder cancer (NMIBC).

---

This podcast is supported by:
Ferring Pharmaceuticals

---

SYNPOSIS

The conversation covers the current challenges of interpreting positive biomarkers without clinical correlates, the gold standard of biopsies, and the potential of various biomarkers such as urine cytology, FISH, and newer genomic tests like the Decipher Bladder Genomic Classifier. They also touch upon the role of AI in pathology, the cost implications of biomarkers, and how these tools might influence future clinical practices and patient decisions. The episode emphasizes the need for precision medicine, careful patient counseling, and the impact of false positives and negatives on both patients and healthcare providers.

---

TIMESTAMPS

00:00 - Introduction
05:25 - Challenges with Current Biomarkers
08:10 - New Biomarkers and Genomic Classifiers
21:10 - AI and Pathology in Bladder Cancer
35:13 - Screening and Future Directions
41:20 - Challenges and Future Directions in Bladder Cancer Surveillance
57:51 - Conclusion

---

RESOURCES

DaBlaCa-15 Trial
https://pubmed.ncbi.nlm.nih.gov/40280776/

Sam Chang CHAI Study
https://pubmed.ncbi.nlm.nih.gov/40514253/

Considering a reconstructive urology fellowship or already in the thick of it? This episode is for you. Dr. Rachel Mann (University of Minnesota) sits down with Dr. George Koch (Ohio State University) to discuss her journey in reconstructive urology and the mentors who shaped it. Together, they explore how creativity, adaptability, and mentorship fuel progress in this evolving subspecialty.
---
SYNPOSIS
Dr. Mann also shares practical advice for residents and fellows who are planning their next steps in training. She reflects on how to identify the right fellowship, make the most of a unique learning year, and transition effectively into independent practice. The episode closes with a discussion of the future of reconstructive urology, including global health opportunities, the potential for dedicated transgender surgery fellowships, and the mindset required to continue evolving as a reconstructive surgeon.
---
TIMESTAMPS
00:00 - Introduction
03:01 - Training and Mentorship
11:09 - The Evolution and Scope of Reconstructive Urology
32:49 - The Future of Reconstructive Urology
35:01 - Expanding Internationally
38:24 - Rapid Fire Advice for Residents
45:59 - Advice for Fellows
---
RESOURCES
The Trauma and Urologic Reconstructive Network of Surgeons (TURNS)
https://www.turnsresearch.org/
Optilume ROBUST III trial
https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.312
RD-180 Suture Device
https://pubmed.ncbi.nlm.nih.gov/35070820/

We have relied on PSA for decades, but what’s next in precision screening for prostate cancer? In this episode of BackTable Urology, Dr. Jason Hafron from the Michigan Institute of Urology joins host Dr. Ruchika Talwar to discuss the evolving role of biomarkers and artificial intelligence in prostate cancer screening.
---
This podcast is supported by:
Cleveland Diagnostics
https://www.isopsa.com/
---
SYNPOSIS
Together, Dr. Hafron and Dr. Talwar examine the ongoing challenges of PSA testing and the promise of next-generation blood-based biomarkers, including 4Kscore and IsoPSA tests. They explore how these advancements are reshaping detection, diagnosis, and risk stratification. The episode also highlights how these tools may improve active surveillance protocols, reduce unnecessary biopsies, and better personalize prostate cancer management for better outcomes.
---
TIMESTAMPS
0:00 - Introduction
2:23 - Limitations of PSA
10:21 - Limitations of MRI
18:08 - Overview of Biomarkers (IsoPSA, 4K, PHI, SelectMDx, MIPS, ExoDx)
26:30 - Artificial Intelligence
---
RESOURCES
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial
https://jamanetwork.com/journals/jama/fullarticle/2817323
Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA
https://pubmed.ncbi.nlm.nih.gov/36965817/
Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study
https://pubmed.ncbi.nlm.nih.gov/35840465/

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.

---

This podcast is supported by:
Ferring Pharmaceuticals

---

SYNPOSIS

The conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes.

---

TIMESTAMPS

00:00 - Introduction
02:04 - The Role of Medical Oncologists in Bladder Cancer
12:58 - Combination Therapies and Patient Outcomes
21:18 - The CREST Study
26:59 - Managing Adverse Events
34:44 - Collaboration Between Urologists and Oncologists
41:06 - Conclusion and Final Thoughts

---

RESOURCES

CREST Trial
https://www.nature.com/articles/s41591-025-03738-z

CISTO Study
https://pubmed.ncbi.nlm.nih.gov/37980511/

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.

---

This podcast is supported by:
Ferring Pharmaceuticals

---

SYNPOSIS

The discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology.

---

TIMESTAMPS

00:00 - Introduction
05:09 - Challenges and Strategies in Treatment
10:55 - Bladder Sparing Therapies
21:41 - Practical Tips for Therapy Administration
30:39 - Challenges and Considerations in Reinduction
37:05 - Clinical Trials and Future Directions
44:11 - Counseling Patients on Treatment Options
57:36 - Concluding Thoughts and Future Outlook

---

RESOURCES

CORE-008 Clinical Trial
https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147

Legend Clinical Trial:
https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.802

CISTO Study
https://pubmed.ncbi.nlm.nih.gov/37980511/

When a patient is diagnosed with non-muscle invasive bladder cancer (NMIBC), how do you tailor the conversation and treatment plan to their individual needs (and fears)? In part two of the 2025 NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam is joined by Dr. Sima Porten from UCSF and Dr. Patrick Hensley from the University of Kentucky to discuss patient-centered diagnostic and therapeutic approaches for non-muscle invasive bladder cancer.

---

This podcast is supported by:
Ferring Pharmaceuticals

---

SYNPOSIS

The conversation covers initial patient consultations, discussing diagnoses, personalized treatment options such as BCG, gemcitabine, clinical trials, and managing side effects. The experts emphasize the importance of clear communication, understanding patient preferences, and tailoring approaches to enhance the patient's quality of life. They also explore insights from recent studies like the CISTO trial and highlight novel research directions.

---

TIMESTAMPS

00:00 - Introduction
04:28 - Counseling Patients on Diagnostic Findings
12:03 - Symptom Management and Patient Care
19:30 - Post-Procedure Care and Counseling
28:50 - Recovery After TURBT: Medications and Patient Care
44:16 - The Impact of Radical Cystectomy on Quality of Life
49:15 - Final Thoughts and Future Directions in Bladder Cancer Care

---

RESOURCES

NIMBUS Study
https://pubmed.ncbi.nlm.nih.gov/32446864/

For patients with ischemic priapism, time to treatment can mean the difference between recovery and long-term dysfunction. In this episode, Dr. Maia VanDyke (UT Southwestern Medical Center) joins host Dr. Juan Andino (UCLA Health) for a high-yield discussion on managing this urologic emergency, from early recognition to advanced surgical options.
---
SYNPOSIS
Together, they cover diagnosis, patient demographics, and traditional versus advanced interventions, with special attention to the role of penoscrotal decompression in prolonged ischemic priapism. The conversation highlights surgical techniques, postoperative care strategies, and patient counseling, including the hard but essential discussions about long-term erectile dysfunction risk. Drs. Andino and VanDyke also emphasize the importance of collaboration, encouraging general urologists to adopt these approaches while leaning on colleagues and centers of excellence for complex cases.
---
TIMESTAMPS
00:00 - Introduction
02:18 - Understanding Priapism
07:52 - Diagnosis and Initial Management
16:51 - Advanced Management and Surgical Interventions
28:21 - Patient Retention Challenges
29:59 - Surgical Planning and Techniques
37:29 - Post-Operative Care and Patient Rehabilitation
44:13 - Future Directions in Research and Treatment
51:28 - The Role of General Urology
---
RESOURCES
Dr. David Ralph article on use of MRI in management of priapism
https://doi.org/10.1111/j.1464-410X.2010.09368.x
Dr. Tom Lue article on corporal aspiration
https://doi.org/10.1038/nrurol.2009.50
Arthur “Bud” Burnett article on corporal tunneling
https://doi.org/10.1016/j.juro.2012.08.245
Allen “Al” Morey article on penoscrotal decompression erectile function outcomes
https://doi.org/10.1111/bju.15127
Survey on current management practices of ischemic priapism
https://doi.org/10.1038/s41443-019-0120-4
Risk factors, diagnosis, and long-term erectile dysfunction outcomes in priapism
https://doi.org/10.1038/s41443-025-01076-9
Video Journal of Sexual Medicine (VJSM) on Penoscrotal decompression: A better method for priapism management
https://www.vjsm.info/videos/all/penoscrotal-decompression-a-better-method-for-priapism-management
Surgical Management of Ischemic Priapism: what are the New Options? https://doi.org/10.1590/S1677-5538.IBJU.2024.0497
The Impact of Immediate Salvage Surgery on Corporeal Length Preservation
https://doi.org/10.1016/j.juro.2018.01.082

How are leading urologic oncologists using advanced biomarkers and artificial intelligence to refine the diagnosis and management of non-muscle invasive bladder cancer (NMIBC)? In the opening episode of our 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt engages in an insightful, in-studio discussion with Dr. Anne Schuckman and Dr. Piyush Agarwal about contemporary strategies and challenges in the diagnosis of non-muscle invasive bladder cancer.

---

This podcast is supported by:

Ferring Pharmaceuticals

---

SYNPOSIS

The doctors emphasize the importance of having an experienced cytopathologist and discuss the use of different biomarkers and imaging modalities in bladder cancer diagnosis. The conversation delves into risk stratification, patient management strategies, and the evolving role of technology and artificial intelligence in enhancing diagnostic accuracy. The experts also share their perspectives on future advancements and their potential impact on clinical practice.

---

TIMESTAMPS

00:00 - Introduction
04:05 - Surveillance and Follow-Up Strategies
10:10 - Biomarkers in Bladder Cancer
18:02 - Blue Light Cystoscopy and Patient Comfort
30:56 - Risk Assessment and Counseling
42:56 - Future of Bladder Cancer Diagnostics
47:00 - Concluding Thoughts

---

RESOURCES

CxBladder Study
https://www.sciencedirect.com/science/article/pii/S1078143923000091

Lars Dyrsakjot Study on Tumor Markers
https://pmc.ncbi.nlm.nih.gov/articles/PMC7690647/

The Bridge Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/

Kidney cancer management is evolving. How are experts adapting? In this installment of BackTable Tumor Board, Dr. Brandon Manley (Urologic Oncology, Moffitt Cancer Center), Dr. Raquibul Hannan (Radiation Oncology, UT Southwestern), and Dr. Rana McKay (Medical Oncology, UC San Diego) join guest host Mark Ball (Urologic Oncology, National Cancer Institute) to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.

---

This podcast is supported by:

Ferring Pharmaceuticals
---

SYNPOSIS

The conversation covers diagnostic dilemmas, navigating the treatment options of surgery, systemic therapy, and radiation, and the importance of a multidisciplinary approach. Through detailed case reviews, the panel highlights practical pearls, emerging clinical trials, and collaborative approaches that exemplify modern kidney cancer care.

---

TIMESTAMPS

0:00 - Introduction
02:20 - Case 1 (Incidental Renal Mass)
16:52 - Case 2 (Bilateral Renal Masses)
37:22 - Case 3 (Locally Advanced Renal Mass)
56:34 - Case 4 (Symptomatic, Metastatic Disease)
01:14:00 - Final Takeaways